AI Portfolio Summary
In 2025 Q4, Squadron Capital Management LLC maintained a portfolio of 33 distinct positions. The most significant new addition to the portfolio was RELMADA THERAPEUTICS, which now represents 13.71% of the total fund value.
Total Positions
33
Quarter
2025 Q4
Top Holding
RLMD (13.7%)
Top 10 Concentration
65.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 33
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RLMD
RELMADA THERAPE...
|
Unknown | 13.71% | — |
#1
Prev: #—
|
7.5 | 6,700,000 | no change |
NEW
|
6,700,000 | $32,361,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
COGENT BIOSCIEN...
|
Unknown | 11.74% | — |
#2
Prev: #—
|
6.7 | 780,000 | no change |
NEW
|
780,000 | $27,705,600 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MAZE
MAZE THERAPEUTI...
|
Unknown | 8.60% | — |
#3
Prev: #—
|
5.4 | 490,000 | no change |
NEW
|
490,000 | $20,300,700 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Unknown | 8.29% | — |
#4
Prev: #—
|
5.3 | 145,000 | no change |
NEW
|
145,000 | $19,553,975 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KALV
KALVISTA PHARMA...
|
Unknown | 4.79% | — |
#5
Prev: #—
|
3.9 | 700,000 | no change |
NEW
|
700,000 | $11,305,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PALI
PALISADE BIO IN...
|
Unknown | 4.48% | — |
#6
Prev: #—
|
3.8 | 4,500,000 | no change |
NEW
|
4,500,000 | $10,575,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
EDGEWISE THERAP...
|
Unknown | 3.68% | — |
#7
Prev: #—
|
3.5 | 350,000 | no change |
NEW
|
350,000 | $8,685,250 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IKT
INHIBIKASE THER...
|
Unknown | 3.67% | — |
#8
Prev: #—
|
3.5 | 4,225,000 | no change |
NEW
|
4,225,000 | $8,661,250 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KOD
KODIAK SCIENCES...
|
Unknown | 3.46% | — |
#9
Prev: #—
|
3.4 | 291,710 | no change |
NEW
|
291,710 | $8,156,212 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Unknown | 3.25% | — |
#10
Prev: #—
|
3.3 | 190,000 | no change |
NEW
|
190,000 | $7,676,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVBP
CALL
ARRIVENT BIOPHA...
|
CALL Option | 2.88% | — |
#11
Prev: #—
|
3.2 | 338,000 | no change |
NEW
|
338,000 | $6,800,560 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Unknown | 2.78% | — |
#12
Prev: #—
|
3.1 | 80,000 | no change |
NEW
|
80,000 | $6,550,400 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UPB
UPSTREAM BIO IN...
|
Unknown | 2.65% | — |
#13
Prev: #—
|
3.1 | 230,650 | no change |
NEW
|
230,650 | $6,262,148 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SPRB
SPRUCE BIOSCIEN...
|
Unknown | 2.58% | — |
#14
Prev: #—
|
3.0 | 70,000 | no change |
NEW
|
70,000 | $6,097,700 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Unknown | 2.00% | — |
#15
Prev: #—
|
2.8 | 105,551 | no change |
NEW
|
105,551 | $4,730,796 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DBVT
DBV TECHNOLOGIE...
|
Unknown | 1.95% | — |
#16
Prev: #—
|
2.8 | 240,000 | no change |
NEW
|
240,000 | $4,600,800 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYBN
CYBIN INC
|
Unknown | 1.82% | — |
#17
Prev: #—
|
2.7 | 525,000 | no change |
NEW
|
525,000 | $4,294,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LPCN
LIPOCINE INC NE...
|
Unknown | 1.80% | — |
#18
Prev: #—
|
2.7 | 530,000 | no change |
NEW
|
530,000 | $4,255,900 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BLTE
BELITE BIO INC
|
Unknown | 1.76% | — |
#19
Prev: #—
|
2.7 | 26,000 | no change |
NEW
|
26,000 | $4,158,960 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GHRS
GH RESEARCH PLC
|
Unknown | 1.70% | — |
#20
Prev: #—
|
2.7 | 315,000 | no change |
NEW
|
315,000 | $4,000,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EPRX
EUPRAXIA PHARMA...
|
Unknown | 1.60% | — |
#21
Prev: #—
|
2.6 | 500,000 | no change |
NEW
|
500,000 | $3,775,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTYX
VENTYX BIOSCIEN...
|
Unknown | 1.57% | — |
#22
Prev: #—
|
2.6 | 410,000 | no change |
NEW
|
410,000 | $3,702,300 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NXTC
NEXTCURE INC
|
Unknown | 1.42% | — |
#23
Prev: #—
|
2.6 | 236,966 | no change |
NEW
|
236,966 | $3,362,548 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
CALL
VERA THERAPEUTI...
|
CALL Option | 1.29% | — |
#24
Prev: #—
|
2.5 | 60,000 | no change |
NEW
|
60,000 | $3,038,400 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WVE
WAVE LIFE SCIEN...
|
Unknown | 1.26% | — |
#25
Prev: #—
|
2.5 | 175,000 | no change |
NEW
|
175,000 | $2,975,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 33 holdings